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HSP70 is a potential target for tumour treatment. HSP70 plays signiﬁcant roles in several biological
processes, including the regulation of apoptosis. In this study, piperidine derivatives were designed as
novel HSP70 inhibitors based on virtual fragment screening performed in Dock 4.0, Discovery Studio 2.5
and SYBYL 6.9. A total of 67 novel piperidine derivatives were synthesized. Cell viability assays were
performed in 16 cancer cell lines. The emphasis was placed on lapatinib-resistant breast cancer cells (BT/
LapR1.0, MDA-MB-361, SK/LapR1.0, and MDA-MB-453). The compounds HSP70-36/37/40/43/46 signiﬁ-
cantly inhibited the proliferation of human breast cancer cells. Compound HSP70-36 inhibited the
growth of BT474 and BT/LapR1.0 cells with IC50 values of 1.41 mM and 1.47 mM, respectively. The binding
afﬁnity of HSP70-36/HSP70 was evaluated by surface plasmon resonance and yielded Kd values of
2.46 mM. The LD50 was 869.0 mgkg1. These data suggest that HSP70-36 may be a potential candidate
compound for tumour treatment.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heat Shock Protein 70 (HSP70) maintains protein homeostasis
by controlling protein quality and turnover during both normal and
stress conditions [1]. Genetic and biochemical studies have impli-
cated HSP70 in a range of diseases and conditions, such as cancer,
allograft rejection, neurodegeneration, and infection, and this va-
riety of conditions may be consistent with HSP70's diverse activ-
ities. HSP70 plays signiﬁcant roles in several biological processes,
including the regulation of apoptosis, via its roles in intrinsic and
extrinsic apoptotic pathways, such as blocking the release of cy-
tochrome c frommitochondria [2] and the binding of death ligands
(Tumour necrosis factor (TNF) and TNF-related apoptosis inducing
ligand (TRAIL)) to their corresponding receptors [3].
Multidrug resistance to chemotherapeutic drugs is an important
reason underlying clinical chemotherapy failure. Consistent with
the hypothesis that HSP70 is involved in cancer resistance during
tumour treatment [4,5], HSP70 has been found to be abundantly
expressed in a variety of human cancers and is often related to
metastasis and poor outcome in cancer patients [6,7]. HSP70 in-
hibitors can reduce or suppress its physiological function in tumour
cells, which may suppress or reduce cancer resistance [7]. Manyngwu@bmi.ac.cn (W. Zhong).
Masson SAS. This is an open accessreports have shown that autophagy plays a protective role in cell
death [8]. RNA-seq results indicated that the genes HSPA1A/B [9],
which can promote autophagy, were signiﬁcantly upregulated in
HYF127c/Cu-treated cells (HSPA1A: fold ¼ 6.3, p ¼ 0.0004). The
mitogen-activated protein kinase (MAPK) 11/12/13/14 inhibitor
SB203580 downregulated autophagy by inhibiting the transcrip-
tion of the autophagy genes HSPA1A, promoted HYF127c/Cu-
induced cell death [8]. Thus, HSPA1A/B likely contributes to
chemotherapy resistance in cancer cells [8].
Only a small number of HSP70 inhibitors have been identiﬁed
[10,11]. In most cases, the active site and mode of binding of these
molecules to HSP70 are unknown [12,13]. Here, we aim to identify
new chemical entities based on the HSP70 N-terminal nucleotide
binding domain for the potential treatment of clinical tumour
resistance. In the next section, we discuss novel small molecules
that were designed based on the N-terminal nucleotide binding
domain that may reduce the viability of resistant cancer cells. These
compounds are novel small molecule drugs that had not been
identiﬁed to date as HSP70 inhibitors.
2. Results and discussion
2.1. Computational studies
The design of small molecule drugs by virtual fragmentarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 2. Binding modes of HSP70-40 at the active site of HSP70 ATPase. The Figure was
generated by the Discovery Studio 2.5 software. The compound HSP70-40 is repre-
sented in stick form, and the blue dotted lines are hydrogen-binding interactions and
Hep interactions. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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approach. Virtual fragment screening and combination virtual li-
brary screening were performed to design novel HSP70 inhibitors.
The skeleton structures of these small molecules, which are novel,
are shown in Fig. 1.
The calculated binding mode of the compound HSP70-40 at
the active site of the HSP70 ATPase domain is shown in Fig. 2,
which was generated with the Discovery Studio 2.5 software. The
ligand docking results showed that the binding pocket involves
the key amino acid residues Thr14, Thr15, Gly205, Arg274 and
Ser278. The N3 atom on the pyridine ring of compound HSP70-
40 donates 2 hydrogen bonds from to the backbone of Thr15
and Gly205. Two hydrogen bonds that formed deep in the ATP-
binding site seem to act as an anchor to facilitate the binding
of compound HSP70-40. Compound HSP70-40 can be further
stabilized in the ATP-binding site by the hydrophobic in-
teractions of its nonpolar groups with the side chains of Gly13,
Tyr16, Gly204, Gly206, Thr207, Ser343, Gly345 and Asp369. Most
small compounds share the key feature of occupying a signiﬁcant
portion of the ATP-binding site.
2.2. Chemistry
All the novel compounds were named by “HSP70-number”, and
the numbering of the compounds in table was simply represented
only by number.
2.2.1. Synthesis of compounds HSP70-(1e20)
Compounds HSP70-(1e20) were synthesized according to the
procedure outlined in Scheme 1. 2-chloro-5-(chloromethyl)thia-
zole (1a) was reacted with tert-butyl methyl (piperidin-4-yl)
carbamate) (2) in the presence of K2CO3 to produce tert-butyl 1-((2-
chlorothiazol-5-yl)methyl)piperidin-4-yl(methyl)carbamate(3a),
which was subsequently transformed into 4a via one successive
substitution reaction. Next, 5awas obtained via the deprotection of
amino groups with triﬂuoroacetic acid in dichloroethane. Amide 5a
was reacted with the corresponding substituted benzyl chloride (6)
to afford HSP70-(1e20) via a substitution reaction.
2.2.2. Synthesis of compounds HSP70-(21e31)
Compounds HSP70-(21e31) were synthesized according to the
procedure outlined in Scheme 2. 3awas subsequently transformed
into 1-((2-chlorothiazol-5-yl)methyl)-N-methylpiperidin-4-
amine(5b) via the deprotection of amino groups with triﬂuoro-
acetic acid in dichloroethane. Amide 5b was reacted with the cor-
responding substituted benzyl chloride (6) to afford HSP70-
(21e34) via a substitution reaction.
2.2.3. Synthesis of compounds HSP70-(32e34)
Compounds HSP70-(32e34) were synthesized according to the
procedure outlined in Scheme 3. 2-chloro-5-(chloromethyl)thia-
zole (1a) and tert-butyl piperidin-4-ylcarbamate (2a) were reactedFig. 1. Skeleton structuresin the presence of K2CO3 to produce tert-butyl 1-((2-chlorothiazol-
5-yl)methyl)piperidin-4-ylcarbamate (3d). Compound 3d was
treated with triﬂuoroacetic acid in dichloroethane and reﬂuxed for
5 h to obtain the intermediate product 1-((2-chlorothiazol-5-yl)
methyl)piperidin-4-amine (5c), followed by an amine substitution
reaction of the intermediate 5cwith substituted benzyl chloride (6)
to yield HSP70-(32e34).
2.2.4. Synthesis of compounds HSP70-(35e56)
Compounds HSP70-(35e56) were synthesized according to the
procedure outlined in Scheme 4. 2,4-dichloropyrimidine(1b) and
tert-butyl methyl (piperidin-4-yl)carbamate) (2) were reacted in
dimethylformamide at room temperature in the presence of K2CO3
to yield tert-butyl 1-(2-chloropyrimidin-4-yl)piperidin-4-
yl(methyl)carbamate(3b). Subsequently, 3b was converted to the
ether via a treatment with CH3SNa or CH3ONa to produce in-
termediates of type 4d. Next, a stirred solution of 4d in dichloro-
ethanewas treatedwith triﬂuoroacetic acid at room temperature to
obtain 5d. Amide 5d was reacted with the corresponding
substituted benzyl chloride (6) to yield HSP70-(35e56) via a sub-
stitution reaction.
2.2.5. Synthesis of compounds HSP70-(57e67)
Compounds HSP70-(57e67) were synthesized according to the
procedure outlined in Scheme 5. 4,6-dichloropyrimidine (1c) was
reacted with tert-butyl methyl (piperidin-4-yl)carbamate) (2) in
the presence of K2CO3 to produce tert-butyl 1-(6-chloropyrimidin-
4-yl)piperidin-4-yl(methyl)carbamate (3c), which was subse-
quently transformed into tert-butyl 1-(6-methoxypyrimidin-4-yl)
piperidin-4-yl(methyl)carbamate (4e) via one successivecontaining piperidine.
Scheme 1. Synthetic pathway of derivatives HSP70-(1e20). Reagents and conditions: (a) DMF, K2CO3, rt., 6 h; (b) R1¼ CH3CH2O: CH3CH2ONa, MeOH, reﬂux, 8 h; R1 ¼ CH3S: CH3SNa,
KI, THF, reﬂux, 10 h; (d) CF3CCOOH, dichloroethane, rt., 5 h; (e) DMF, K2CO3, rt., 4 h.
Scheme 2. Synthetic pathway of derivatives HSP70-(21e31). Reagents and conditions: (d) CF3CCOOH, dichloroethane, rt., 5 h; (e) DMF, K2CO3, rt., 4 h.
Scheme 3. Synthetic pathway of derivatives HSP70-(32e34). Reagents and conditions: (a) DMF, K2CO3, rt., 6 h; (d) CF3CCOOH, dichloroethane, rt., 5 h; (e) DMF, K2CO3, rt., 4 h.
Scheme 4. Synthetic pathway of derivatives HSP70-(35e56). Reagents and conditions: (a) DMF, K2CO3, rt., 6 h; (b) R1 ¼ CH3CH2O: CH3ONa, MeOH, reﬂux, 8 h; R1 ¼ CH3S: CH3SNa,
KI, THF, reﬂux, 10 h; (d) CF3CCOOH, dichloroethane, rt., 5 h; (e) DMF, K2CO3, rt., 4 h.
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N-methylpiperidin-4-amine (5e)was obtained via the deprotection
of amino groups with triﬂuoroacetic acid in dichloroethane, fol-
lowed by the amine substitution reaction of intermediate 5e with
substituted benzyl chloride (6) to afford HSP70-(57e67).2.3. Cell viability assay
As previously reported, HSP70 over expression has been asso-
ciated with poor prognosis in multiple forms of cancer and is
thought to offer a survival advantage to cancer cells by interacting
Scheme 5. Synthetic pathway of derivatives HSP70-(57e67). Reagents and conditions: (a) DMF, K2CO3, rt., 6 h; (b) CH3ONa, MeOH, reﬂux, 8 h; (d) CF3CCOOH, dichloroethane, rt.,
5 h; (e) DMF, K2CO3, rt., 4 h.
Table 1
IC50 values of compounds in BT474 and BT/LapR1.0 human breast cancer cells.
Y. Zeng et al. / European Journal of Medicinal Chemistry 97 (2015) 19e3122with multiple components of both caspase-dependent and
caspase-independent apoptotic pathways [14,15]. To identify mol-
ecules that induce apoptosis in cells, 67 piperidine derivatives were
evaluated in six breast cancer cell lines, including BT474, BT/
LapR1.0, MDA-MB-361, SK-BR3, SK/LapR1.0 and MDA-MB-453. A
dose exceeding the IC50 was selected to improve the detection of
cell viability. Lapatinib is used in combination with capecitabine to
treat advanced or metastatic breast cancers that express high levels
of ErbB-2 or are resistant to anthracycline, paclitaxel or trastuzu-
mab (Herceptin). Therefore, lapatinib was selected as a positive
control in the cell viability assay. Furthermore, emphasis was
placed on lapatinib-resistant breast cancer cells (BT/LapR1.0, MDA-
MB-361, SK/LapR1.0 and MDA-MB-453), whose data may be more
clinically applicable. As shown in Fig. 3, inhibitors HSP70-36/37/40/
43/46 demonstrated signiﬁcantly potent anti-cancer activities
against the six breast cancer cell lines, especially the lapatinib-
resistant breast cancer cells (lapatinib 1 mM). Therefore, the scaf-
folds of these piperidine derivatives will be further probed to
improve their activity. Speciﬁcally, a dose of 5 mM achieved inhib-
itory rates of more than 50% of the piperidine derivatives in MDA-
MB-453 cells, indicating that most of these compounds were
cytotoxic to MDA-MB-453 cells. IC50 values were also measured in
BT474 and BT/LapR1.0 human breast cancer cells and are shown in
Table 1.
We also assessed the abilities of HSP70-36/37/40/43/46 to
induce cell death in several other cancer cell lines, including he-
patocellular carcinoma (HepG2 and Huh-7), gastric cancer (N87
and BGC823), pancreatic cancer (AsPC-1 and MIA-PaCa-2), colo-
rectal cancer (COLO205 and HT-29), lung cancer (A549 and H460)
and normal cell lines (human embryonic lung ﬁbroblastWI-38 cells
and lung epithelial ﬁbroblast MRC5 cells). The test samples were
diluted to ﬁnal concentrations of 4, 1, 0.25, 0.063, and 0.016 mM andFig. 3. Inhibitory rates of piperidine derivatives in BT474, BT/LapR1.0, MDA-MB-361,
SK-BR3, SK/LapR1.0 and MDA-MB-453 cells at 5 mM.added to wells containing 50 mL of medium. Samples were set up in
triplicate, and cells were incubated for 72 h at 37 C. As shown in
Fig. 4, compounds HSP70-36/43 somewhat inhibited and were
cytotoxic to both tumour and normal cells, and these effects did not
differ between cell types. Compounds HSP70-37/40/46 exerted a
slightly stronger effect on hepatocellular carcinoma cells than other
cancer cells. Moreover, the cytotoxicity was lower to normal cells
than to other tumour cells, indicating that these compounds may
have fewer side effects.
2.4. SPR studies
To understand the molecular basis by which piperidine de-
rivatives induce apoptosis, surface plasmon resonance (SPR)
studies of HSP70 inhibitors were performed using an optical
biosensor Biacore T100 (GE), as reported elsewhere [16,17]. This
process was ﬁrst highlighted in mass-based chemical experiments.
The exponential curves produced according to concentration-
dependent responses during both the association and dissociation
phases indicated efﬁcient interactions with immobilized HSP70
protein. Each compound was examined at different concentrations
(0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 mM), T ¼ 25 C and 5%
dimethyl sulfoxide (assay buffer). A typical analysis cycle consisted
of a 90 s sample injection (30 ml/min) and 120 s of buffer ﬂow
(dissociation phase). The dissociation constant (Kd value) for Ver-
155008/HSP70 was determined to be 0.2060 mM, which is similar
to the reported 0.3 mM value [18]. As shown in Table 2, the ther-
modynamic dissociation constants (Kd values) for HSP70-12/HSP70
and HSP70-36/HSP70 were 0.1999 mM and 0.2463 mM, respectively,Name R BT474 (mM) BT/LapR1.0 (mM)
36 P-cyanobenzyl 1.41 1.47
37 2-chloro-6-ﬂuoro-benzyl 1.04 0.94
40 2,4-dichlorobenzyl 1.62 1.68
43 2,6-dichlorobenzyl 0.78 0.70
46 2-chlorobenzyl 1.99 1.70
Fig. 4. Survival rates of HepG2, Huh-7, N87, BGC823, AsPC-1, MIA-PaCa-2, COLO205, HT-29, A549, H460 and normal cell lines (WI-38 and MRC5) exposed to different concentrations
of compounds HSP70-36/37/40/43/46.
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positive control Ver-155008 at 10 mM. Furthermore, HSP70-36
inhibited the proliferation of human breast cancer cells BT474
and BT/LapR1.0 with IC50 values of 1.41 mM and 1.47 mM, respec-
tively. Both results identiﬁed HSP70 as the main HSP70-36 target in
cancer cells. Thus, compound HSP70-36 may prolong the survival
time of cancer patients by inhibiting HSP70.
2.5. Colorimetric determination of HSP70 ATPase activity
To examine the ability of the tested compounds to act on the
HSP70 ATPase domain, the HSP70 ATPase activity was evaluated
using an assay outlined in previous reports with somemodiﬁcations [19]. In the preliminary screening system, the com-
pounds that inhibited HSP70 ATPase activity by 20% at a concen-
tration of 200 mM were deﬁned as effective inhibitors [20,21]. Two
positive control compounds were used to verify the accuracy of the
screening system. The inhibition rate of the control compounds AZ
and VER155008 reached 53.13% and 43.03%, respectively, indicating
the high efﬁcacy and accuracy of the experimental system. Dose-
dependent effects were observed for various concentrations of
the positive controls incubated with HSP70 (Fig. 5). HSP70-37 was
identiﬁed as a potential inhibitor because its inhibition rate
exceeded 20% inmultiple experiments. Other compounds could not
effectively inhibit the ATPase turnover (Table 3). Therefore, the SPR
and ATPase activity results indicate that the piperidine derivatives
Table 2
Kinetic characterization of inhibitor binding to HSP70.a
Name Kd (molL1)
VER-155008 2.060  107
12 1.999  107
14 2.454  106
35 2.045  106
36 2.463  107
56 2.811  106
a To determine the afﬁnities and kinetic rate constants,
each compound was examined at different concentrations
(0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 mM), T ¼ 25 C and
5% dimethyl sulfoxide (assay buffer). A typical analysis
cycle consisted of a 90 s sample injection (30 mlmin1) and
120 s of buffer ﬂow (dissociation phase).
Table 3
Inhibition rate of compounds (200 mM) on HSP70 ATPase.
Name Inhibition rate (%) SD
4 5.49 8.04
8 4.5 15.32
12 10.59 8.52
16 10.74 11.51
19 6.21 9.32
22 11.28 1.34
35 7.73 2.52
36 8.14 2.72
37 20.39 3.31
40 8.28 10.58
41 16.67 1.6
43 12.81 4.41
46 11.63 4.64
47 6.11 5.05
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pounds may not act on the HSP70 ATPase domain. Identifying the
speciﬁc site on HSP70 which these piperidine derivatives act re-
quires more in-depth studies. Further genetic testing may also be
required.
2.6. Acute toxicity test by single oral gavage with HSP70-36 in mice
We tested the acute toxicity of HSP70-36 by treatingmice with a
single oral gavage. Mice that received HSP70-36 at 1555 mg/kg
were dead after 5 min. None of the control mice died from d 1 to
d 14, which was the end of the test. We observed 10, 9, 8, 5, 4, 1 and
0 deaths in the groups treated with 1555, 1296, 1080, 900, 750, 625
and 520 mg/kg HSP70-36, respectively (Table 4). No obvious ab-
normalities were observed from the organ coefﬁcients at the end of
the experiment. Using the Bliss method [22,23], the LD50 was
calculated to be 869.0 mg*kg1 with 95% a conﬁdence interval of
776.5e969.4 mg*kg1.
3. Conclusions
Novel piperidine derivatives signiﬁcantly inhibit the growth of
lapatinib-resistant breast cancer cells and other tumour cell lines,
indicating that they may be effective clinical therapies for drug-
resistant breast cancer patients by targeting HSP70. The R1 of ring
A was substituted from a thiazole to a pyrimidine. Pyrimidine is
more active than thiazole. The methylthio group at the position R1
was well suitable to the function of the compound. These sub-
stituents exhibited better anti-tumour activity than substitutions
with halogens, such as chlorine and ﬂuorine. However, the position
of the substituent is critical because the inhibition rate markedly
decreased when 2-subsitituents were changed to 4-subsitituents.
Placing R3 of ring C in the ortho and/or para rather than intero
position improved the anti-tumour activity.Fig. 5. Percentage of inhibition of HSP70 ATPase activity achieved by diThese piperidine derivatives showed good anticancer bio-
activities with a very low inhibiting rate of the HSP70 ATPase.
However, these compounds showed moderate binding to HSP70.
Therefore, these compounds did not interact with the HSP70
ATPase domain while acting on HSP70. An allosteric site on the
HSP70 N-terminal nucleotide binding domain has been reported
[24,25]. We identiﬁed this allosteric site as the purple areas shown
in Fig. 6. In other words, the virtual screening domain included the
allosteric site and ATPase domain, which indicates that these
compounds may have acted on the allosteric site. Therefore, these
compounds affect HSP70 function without affecting ATPase, which
allows them to inhibit the growth of tumour cells. Nevertheless, in-
depth studies are required to clarify the mechanism of action.
These ﬁndings may be relevant to the possible therapeutic ap-
plications of piperidine derivatives and design of new therapeutic
approaches. Our ﬁndings may hold key importance for the devel-
opment of effective HSP70 inhibitors. Based on the determination
of dissociation constants, we can examine how these compounds
suppress the viability of cancer cells by inhibiting HSP70, which can
provide a favorable clinical proﬁle. In addition, the identiﬁcation of
piperidine derivatives as inhibitors of HSP70 suggests that these
compounds may serve as a new tool to further explore the biology
of this chaperone protein and perhaps help unravel the affected
complex processes.
4. Experimental section
4.1. Computational methods
The crystal structures of the nucleotide binding domain (NBD)
in complex with ADP (adenosine diphosphate) were recovered
from the Brookhaven Protein Data Bank (http://www.rcsb.org/pdb/fferent concentrations of the positive controls VER 155008 and AZ.
Table 4
Number of surviving and deceased mice in each dose group.
ID Dose mgkg1 Number of animals (survived/dead)
Male Female
1 1555 0/5 0/5
2 1296 1/4 0/5
3 1080 0/5 2/3
4 900 3/2 2/3
5 750 4/1 2/3
6 625 4/1 5/0
7 520 5/0 5/0
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detected using the MVD4.0 software and divided into red, yellow
and purple areas for virtual fragment screening (Fig. 6). The red and
yellow areas constituted the domain that the ADP acted on. The
fragment libraries were taken from the Cambridge database and
our patented compound library containing a total of 243,712
compounds. The receptor ﬁles were prepared in Chimera. The grid-
based energy scoring function was used to judge the afﬁnity of the
fragment for HSP70. The energy-scoring component of Dock 4.0
was based on the implementation of force ﬁeld scoring. Force ﬁeld
scores are approximate molecular mechanics interaction energies,
consisting of van der Waals and electrostatic components:
DGbindingzDHbinding. Anchor-ﬁrst search was used for small mole-
cule conformation searches. Optimization fragments were selected
with critical site point matching, chemical matching and energy
minimization. A virtual combination library was established using
the module Reaction of Enumerate Library of Discovery Studio 2.5.
ADMET screening was used to estimate a range of ADMET-related
properties for small molecules, and we excluded compounds with
poor druggability. Precise docking was then performed on the
Surﬂex-Dock of SYBYL 6.9. The geometries of these compounds
were subsequently optimized using the Tripos force ﬁeld [27] with
Gasteiger-Hückel charges. The Powell method encoded in SYBYL 6.9
was used for energy minimization under an 8 Å nonbonded cutoff
and an energy convergence gradient value of 0.005 kcal/(mol Å).
The 3D grid was established by the AutoGrid algorithm to evaluate
the binding energies between the inhibitors and HSP70 ATPase
domain. The number of generations, energy evaluations, and
docking runs were set to 380000, 1600000, and 20, respectively.
The atomic charges used were Gasteiger-Hückel [27] for the in-
hibitors and Kollmal-all-atom for HSP70 NBD. Precise docking was
then performed on the Surﬂex-Dock of SYBYL 6.9.Fig. 6. Active pocket of HSP70 ATPase domain with ADP. The nucleoside binding
domain is divided into red, yellow and purple areas for virtual screening using Dock
4.0. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)4.2. General chemistry
1H NMR spectra were recorded in CDCl3-d on a Bruker-ARX300
spectrometer with TMS as an internal standard. 13C NMR spectra
were recorded in DMSO-d6 on a Bruker-arx400 spectrometer. All
chemical shifts are quoted in d values (ppm). MS spectra were
recorded using a Micromass ZabSpect. Reagents and solvents were
purchased from common commercial suppliers.4.2.1. General procedure for the synthesis of compounds HSP70-
(1e20)
General procedure 1: 8.40 g (50 mmol) of 2-Chloro-5-(chlor-
omethyl)thiazole,10.70 g (50mmol) of tert-butyl methyl(piperidin-
4-yl)carbamate, and 6.90 g (50 mmol) of anhydrous K2CO3 were
added to a 1000 ml three-necked ﬂask containing 300 ml of
dimethyl formamide (DMF). The mixture was stirred at room
temperature for 6 h. A large amount of ice water was added to
precipitate a solid. The solid was washed with large amounts of
petroleum ether, ﬁltered, and dried in a vacuum. A white powder
consisting of N-methyl-N-{1-[(2-chloro-5-thiazolyl) methyl]-4-
piperidinyl} carbamic acid tert-butyl ester (3a) (16.90 g) was ob-
tained (yield 98%).
A solution of 3a (6.92 g, 20mmol) in anhydrous ethanol (100ml)
was treated with sodium ethoxide or sodium methyl mercaptan
(25 mmol) and reﬂuxed for 8 h. The mixture was cooled to room
temperature in a water bath. Solvent was removed under a vacuum
at 50 C. The residue was dissolved in water, extracted with ethyl
acetate, dried over anhydrous MgSO4, and ﬁltered. The organic
phasewas removed under a vacuum at 45 C to obtain colorless oily
substance 4a or 4b.
Compound 4a (10 mmol) was dissolved in dichloromethane
(50 ml), and an excess of triﬂuoroacetic acid was added in an ice
bath. The mixture was stirred at room temperature for 5 h. The
solvent was removed in a vacuum at 40 C to obtain yellow oily
substance of 5a.
A solution of compound 5a (0.2 mmol) was dissolved in DMF
(5 ml). Anhydrous K2CO3 (0.2 mmol) and benzyl chloride
(0.2 mmol) were added, and the mixture was stirred at room
temperature for 4 h. Water (40 ml) was added, and the compound
was extracted with dichloromethane, dried with Na2SO4, and the
solvent was removed to produce a colorless oily substance, HSP70-
(1-20).4.2.1.1. N-(3-Chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-1). 1H NMR (300 MHz, CDCl3-d):
d1.46e1.43 (t, J ¼ 7.2 Hz, 3H); d1.67e1.64 (m,2H); d1.82e1.79
(m,2H); d2.03e1.98 (m,2H); d2.21 (s,3H); d2.44 (m,1H); d3.01e2.99
(m,2H); d3.56 (s,4H); d4.46e4.41 (q, J ¼ 7.2 Hz, 2H); d6.90 (s,1H);
d7.35e7.22 (m,4H). MS(TOF) 379.9 (Mþ).4.2.1.2. 2-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-2). 1H NMR (300 MHz, CDCl3-
d): d1.45e1.42 (t,3H); d1.70e1.69 (m,2H); d1.82 (m,2H); d2.02
(m,2H); d2.22 (s,3H); d2.51 (m,1H); d3.02e2.99 (m,2H); d3.56
(s,2H); d3.78 (s,2H); d4.46e4.40 (q,2H); d6.90 (s,1H); d7.64e7.28
(m,4H). MS(TOF) 370.5 (Mþ).4.2.1.3. N-(3,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-3). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.46 (t,3H); d1.63e1.66 (m,2H); d1.77e1.80 (d,2H); d2.00
(t,2H); d2.20 (s,3H); d2.43 (m,1H); d2.98e3.01 (d,2H); d2.53e3.56
(d,4H); d4.41e4.46 (m,2H); d6.90 (s,1H); d7.15e7.18 (dd,1H);
d7.37e7.39 (d,2H); d7.44e7.75 (d,1H). MS(TOF) 414 (Mþ).
Y. Zeng et al. / European Journal of Medicinal Chemistry 97 (2015) 19e31264.2.1.4. 4-(((1-((2-Ethoxythiazol-5-yl)methyl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-4). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.46 (t,3H); d1.63e1.67 (m,2H); d1.77e1.81 (d,2H);
d1.98e2.03 (t,2H); d2.20 (s,3H); d2.43 (m,1H); d2.98e3.01 (d,2H);
d3.56e3.63 (d,4H); d4.40e4.46 (m,2H); d6.90 (s,1H); d7.44e7.46
(d,2H); d7.60e7.62 (d,2H). MS(TOF) 370.5 (Mþ).
4.2.1.5. N-(2-chloro-6-ﬂuorobenzyl)-1-((2-ethoxythiazol-5-yl)
methyl)-N-methylpiperidin-4-amine (HSP70-5). 1H NMR (300 MHz,
CDCl3-d) d1.43e1.46 (t,3H); d1.72e1.75 (m,2H); d1.84e1.87 (d,2H);
d2.00e2.03 (t,2H); d2.26 (s,3H); d2.53 (m,1H); d3.01e3.04 (d,2H);
d3.58 (s,2H); d3.73 (s,2H); d4.41e4.46 (m,2H); d6.91 (s,1H);
d6.98e6.99 (m,1H); d7.18e7.28 (m,2H). MS(TOF) 397.9 (Mþ).
4.2.1.6. N-(2-chlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-6). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.46 (t,3H); d1.67e1.71 (m,2H); d1.82e1.85 (d,2H);
d1.99e2.04 (t,2H); d2.26 (s,3H); d2.49 (m,1H); d2.99e3.02 (d,2H);
d3.56 (s, 2H); d3.70 (s,2H); d4.41e4.46 (m,2H); d6.91 (s,1H);
d7.17e7.20 (m,1H); d7.22e7.24 (m,1H); d7.22e7.24 (m,1H);
d7.33e7.35 (dd,1H); d7.49 (dd,1H). MS(TOF) 379.9 (Mþ).
4.2.1.7. 1-((2-Ethoxythiazol-5-yl)methyl)-N-(4-ﬂuorobenzyl)-N-
methylpiperidin-4-amine (HSP70-7). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.46 (t,3H); d1.68e1.69 (m,2H); d1.80 (d,2H); d1.98e2.03
(t,2H); d2.21 (s,3H); d2.45 (m,1H); d2.98e3.01 (d,2H); d3.56 (s,4H);
d4.41e4.46 (m,2H); d6.90 (s,1H); d6.98e7.03 (t,2H); d7.28e7.30
(d,2H). MS(TOF) 363.5 (Mþ).
4.2.1.8. N-(2,4-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-8). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.46 (t,3H); d1.61e1.69 (m,2H); d1.80e1.83 (d,2H);
d1.99e2.04 (t,2H); d2.24 (s,3H); d2.47 (m,1H); d2.99e3.02 (d,2H);
d3.57 (s,2H); d3.65 (s,2H); d4.41e4.46 (m,2H); d6.91 (s,1H);
d7.21e7.23 (dd,1H); d7.36 (d,1H); d7.45 (d,1H). MS(TOF) 414.4 (Mþ).
4.2.1.9. N-(2,6-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-9). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.46 (t,3H); d1.78e1.84 (m,4H); d2.05 (m,2H); d2.26 (s,3H);
d2.56 (m,1H); d3.01e3.06 (m,2H); d3.59 (m,2H); d3.85 (s,2H);
d4.43e4.45 (m,2H); d6.92 (s,1H); d7.14e7.16 (m,1H); d7.30e7.31
(m,3H). MS(TOF) 414.4 (Mþ).
4.2.1.10. N-(2,5-dichlorobenzyl)-1-((2-ethoxythiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-10). 1H NMR (300 MHz, CDCl3-d)
d1.42e1.44 (t,3H); d1.66e1.69 (m,2H); d1.81 (m,2H); d2.02 (m,2H);
d2.26 (s,3H); d2.48 (m,1H); d3.00e3.03 (m,2H); d3.58 (s,1H); d3.65
(s,1H); d4.09e4.46 (m,2H); d6.92 (s,1H); d7.16e7.17 (m,1H);
d7.27e7.28 (m,1H); d7.54 (s,3H). MS(TOF) 414.4 (Mþ).
4.2.1.11. N-methyl-N-(2-methylbenzyl)-1-((2-(methylthio)thiazol-5-
yl)methyl)piperidin-4-amine (HSP70-11). 1H NMR (300 MHz, CDCl3-
d): d1.71e1.72 (m,2H); d1.82 (d,2H); d2.03e2.04 (t,2H); d2.20
(s,3H); d2.37 (s,3H); d2.47 (m,1H); d2.70 (s,3H); d2.98e3.01 (d,2H);
d3.57 (s,2H); d3.67 (s,2H); d7.16e7.17 (m,3H); d7.29 (m,1H); d7.42
(s,1H). MS(TOF) 361.6 (Mþ).
4.2.1.12. N-methyl-N-(4-methylbenzyl)-1-((2-(methylthio)thiazol-5-
yl)methyl)piperidin-4-amine (HSP70-12). 1H NMR (300MHz, CDCl3-
d): d1.67e1.68 (m,2H); d1.80 (d,2H); d1.99e2.01 (t,2H); d2.21
(s,3H); d2.35 (s, 3H); d2.45 (m,1H); d2.69 (s,3H); d2.97e2.99 (d,2H);
d3.56 (s,2H); d3.66 (s,2H); d7.12e7.14 (d,2H); d7.20e7.28 (d, 2H);
d7.41 (s,1H). MS(TOF) 361.6 (Mþ).4.2.1.13. N-(3-ﬂuorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-
yl)methyl)piperidin-4-amine (HSP70-13). 1H NMR (300MHz, CDCl3-
d): d1.63e1.67 (m,2H); d1.79e1.82 (d,2H); d1.99e2.05 (t,2H); d2.22
(s,3H); d2.45 (m,1H); d2.69 (s,3H); d2.97e3.00 (d,2H); d3.58 (s,2H);
d3.67 (s,2H); d6.93e6.94 (t,2H); d7.06e7.10 (m,2H); d7.26e7.28
(m,1H); d7.42 (s,1H). MS(TOF) 365.5 (Mþ).
4.2.1.14. N-(3-chlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-
yl)methyl)piperidin-4-amine (HSP70-14). 1H NMR (300MHz, CDCl3-
d): d1.63e1.70 (m,2H); d1.79e1.82 (d,2H); d1.99e2.05 (t,2H); d2.22
(s,3H); d2.44 (m,1H); d2.69 (s,3H); d2.97e3.00 (d,2H); d3.56 (s,2H);
d3.66 (s,2H); d7.21e7.24 (m,3H); d7.34 (s,1H); d7.42 (s, 1H); d7.42
(s,1H). MS(TOF) 382 (Mþ).
4.2.1.15. N-(4-ﬂuorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-5-
yl)methyl)piperidin-4-amine (HSP70-15). 1H NMR (300MHz, CDCl3-
d): d1.63e1.67 (m,2H); d1.79e1.82 (d,2H); d1.99e2.05 (t,2H); d2.20
(s,3H); d2.44 (m,1H); d2.69 (s,3H); d2.97e3.00 (d,2H); d3.55 (s,2H);
d3.66 (s,2H); d6.99e7.02 (t,2H); d7.26e7.30 (t,2H); d7.41 (s,1H).
MS(TOF) 365.5 (Mþ).
4.2.1.16. N-(3,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-
5-yl)methyl)piperidin-4-amine (HSP70-16). 1H NMR (300 MHz,
CDCl3-d): d1.62e1.66 (m,2H); d1.79 (d,2H); d2.00 (t,2H); d2.20
(s,3H); d2.37e2.46 (m,1H); d2.69 (s,3H); d2.97e3.00 (d,2H); d3.37
(s,2H); d3.84 (s,2H); d.02e7.17 (d,1H); d7.37e7.72 (m,3H). MS(TOF)
416.4 (Mþ).
4.2.1.17. N-(2-chloro-6-ﬂuorobenzyl)-N-methyl-1-((2-(methylthio)
thiazol-5-yl)methyl) piperidin-4-amine (HSP70-17). 1H NMR
(300 MHz, CDCl3-d): d1.71e1.75 (m,2H); d1.84e1.87 (m,2H);
d2.02e2.05 (m,2H); d2.26 (s,3H); d2.52 (m,1H); d2.69 (s,3H);
d3.00e3.03 (d,2H); d3.68 (s,2H); d3.72 (s,2H); d6.98e6.99 (m,1H);
d7.17e7.20 (m,2H); d7.42 (s,1H). MS(TOF) 416.4 (Mþ).
4.2.1.18. N-(2,6-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-
5-yl)methyl)piperidin-4-amine (HSP70-18). 1H NMR (300 MHz,
CDCl3-d): d1.72e1.76 (m,2H); d1.83e1.86 (m,2H); d2.02e2.08
(m,2H); d2.25 (s,3H); d2.55 (m,1H); d2.69 (s,3H); d3.00e3.03
(d,2H); d3.68 (s,2H); d3.85 (s,2H); d7.12e7.14 (m,1H); d7.28e7.30
(m,2H); d7.42 (s,1H). MS(TOF) 416.4 (Mþ).
4.2.1.19. N-(2,4-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thiazol-
5-yl)methyl)piperidin-4-amine (HSP70-19). 1H NMR (300 MHz,
CDCl3-d): d1.42e1.44 (m,3H); d1.66e1.69 (m,2H); d1.81 (m,2H);
d2.02 (m,2H); d2.26 (s,3H); d2.48 (m,1H); d3.00e3.03 (d,2H); d3.58
(s,1H); d3.65 (s,1H); d4.41e4.46 (m,2H); d6.91 (s,1H); d7.16e7.17
(m,1H); d7.25e7.27 (m,1H); d7.54 (s,1H). MS(TOF) 416.4 (Mþ).
4.2.1.20. N-(2,5-dichlorobenzyl)-N-methyl-1-((2-(methylthio)thia-
zol-5-yl)methyl)piperidin-4-amine (HSP70-20). 1H NMR (300 MHz,
CDCl3-d): d1.68e1.69 (m,2H); d1.81 (m,2H); d2.04 (m,2H); d2.26
(s,3H); d2.47 (m,1H); d2.69 (s,1H); d2.98e3.01 (m,2H); d3.65e3.68
(m,4H); d7.14e7.17 (m,1H); d7.27e7.28 (m,1H); d7.42 (s,1H); d7.54
(s,1H). MS(TOF) 416.4 (Mþ).
4.2.2. General procedure for the synthesis of compounds HSP70-
(21e31)
General procedure 2: Tert-butyl 1-((2-chlorothiazol-5-yl)
methyl)piperidin-4-yl(methyl) carbamate (3a, 3.46 g,10mmol) was
dissolved in dichloromethane (50 ml), and an excess of triﬂuoro-
acetic acid was added in an ice bath. The mixture was stirred at
room temperature for 5 h. Solvent was removed under a vacuum to
obtain a yellow oily substance consisting of 1-((2-chlorothiazol-5-
yl)methyl)-N-methylpiperidin-4-amine. A stirred solution of 5b
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substituted benzyl chloride (0.51 mmol) and anhydrous K2CO3
(0.51 mmol) for 4 h. The solution was extracted with dichloro-
methane, dried with anhydrous MgSO4, ﬁltered, and concentrated
to produce a yellow oily residue that was puriﬁed by ﬂash chro-
matography to yield the desired product as awhite powder, HSP70-
(21e31).
4.2.2.1. 2-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-21). 1H NMR (300 MHz, CDCl3-
d): d1.66e1.70 (m,2H); d1.84e1.87 (d,2H); d2.03e2.09 (t,2H); d2.22
(s,3H); d2.52 (m,1H); d2.98e3.01 (d,2H); d3.65 (s,2H); d3.79 (s,2H);
d7.34e7.37 (m,2H); d7.55e7.57 (m,2H); d7.63e7.65 (d,2H). MS(TOF)
360.9 (Mþ).
4.2.2.2. 4-(((1-((2-Chlorothiazol-5-yl)methyl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-22). 1H NMR (300 MHz, CDCl3-
d): d1.62e1.66 (m,2H); d1.78e1.81 (d,2H); d1.99e2.05 (t,2H); d2.18
(s,3H); d2.43 (m,1H); d2.69 (s,3H); d2.69e3.00 (d,2H); d3.62e3.67
(d, 4H); d7.41 (s,1H); d7.44e7.46 (d,2H); d7.60e7.62 (d,2H). MS(TOF)
360.9 (Mþ).
4.2.2.3. 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-ﬂuorobenzyl)-N-
methylpiperidin-4-amine (HSP70-23). 1H NMR (300 MHz, CDCl3-d):
d1.64e1.71 (m,2H); d1.80e1.83 (d,2H); d2.01e2.07 (t,2H); d2.20
(s,3H); d2.45 (m,1H); d2.97e3.00 (d,2H); d3.56 (s,2H); d3.65 (s,2H);
d6.98e7.03 (t,2H); d7.27e7.316 (m,2H); d7.34 (s,1H). MS(TOF) 353.9
(Mþ).
4.2.2.4. 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)-N-
methylpiperidin-4-amine (HSP70-24). 1H NMR (300 MHz, CDCl3-d):
d1.62e1.69 (m, 2H); d1.80e1.82 (d,2H); d2.01e2.07 (t,2H); d2.20
(s,3H); d2.44 (m,1H); d2.97e3.00 (d,2H); d3.54 (s,2H); d3.65 (s, 2H);
d7.16e7.18 (d,1H); d7.35e7.39 (m,2H); d7.45 (d,1H). MS(TOF) 404.8
(Mþ).
4.2.2.5. N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)-N-
methylpiperidin-4-amine (HSP70-25). 1H NMR (300 MHz, CDCl3-d):
d1.64e1.71 (m,2H); d1.82e1.85 (d,2H); d2.02e2.08 (t,2H); d2.22
(s,3H); d2.47 (m,1H); d2.97e3.00 (d,2H); d3.60 (s,2H); d3.65 (s,2H);
d7.23 (m,3H); d7.35e7.36 (m,2H). MS(TOF) 370.3 (Mþ).
4.2.2.6. N-(2-chloro-6-ﬂuorobenzyl)-1-((2-chlorothiazol-5-yl)
methyl)-N-methylpiperidin-4-amine (HSP70-26). 1H NMR
(300 MHz, CDCl3-d): d1.74e1.75 (m,2H); d1.85 (d,2H); d2.07 (t,2H);
d2.26 (s,3H); d2.54 (m, 1H); d3.00e3.03 (d,2H); d3.67 (s,2H); d3.74
(s,2H); d6.99 (m,1H); d7.19e7.21 (m,2H); d7.34 (s,1H). MS(TOF)
388.3 (Mþ).
4.2.2.7. 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,4-dichlorobenzyl)-N-
methylpiperidin-4-amine (HSP70-27). 1H NMR (300 MHz, CDCl3-d):
d1.45 (m,2H); d1.68e1.69 (m,2H); d2.02e2.08 (t,2H); d2.25 (s,3H);
d2.47 (m,1H); d2.98e3.01 (d,2H); d3.65 (s,4H); d7.22e7.25 (m,1H);
d7.35e7.37 (m,2H); d7.45 (s,1H). MS(TOF) 404.8 (Mþ).
4.2.2.8. 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(2-
methylbenzyl)piperidin-4-amine (HSP70-28). 1H NMR (300 MHz,
CDCl3-d): d1.71e1.72 (m,2H); d1.83 (d,2H); d2.05e2.06 (t,2H); d2.20
(s,3H); d2.37 (s, 3H); d2.48 (m,1H); d2.98e3.01 (d,2H); d3.58 (s,2H);
d3.66 (s,2H); d7.16e7.17 (m,3H); d7.29 (m,1H); d7.35 (s,1H). MS(TOF)
349.9 (Mþ).
4.2.2.9. 1-((2-Chlorothiazol-5-yl)methyl)-N-methyl-N-(4-
methylbenzyl)piperidin-4-amine (HSP70-29). 1H NMR (300 MHz,
CDCl3-d): d1.67 (m,2H); d1.82 (d,2H); d2.04 (t,2H); d2.22 (s,3H);d2.35 (s,3H); d2.47 (m,1H); d2.97e3.00 (d,2H); d3.57 (s,2H); d3.64
(s,2H); d7.13e7.15 (d,2H); d7.21e7.23 (d,2H); d7.34 (s,1H). MS(TOF)
349.9 (Mþ).
4.2.2.10. 1-((2-Chlorothiazol-5-yl)methyl)-N-(3-ﬂuorobenzyl)-N-
methylpiperidin-4-amine (HSP70-30). 1H NMR (300 MHz, CDCl3-d):
d1.63e1.67 (m,2H); d1.80e1.83 (d,2H); d2.01e2.07 (t,2H); d2.22
(s,3H); d2.46 (m,1H); d2.97e3.00 (d,2H); d3.59 (s,2H); d3.65 (s,2H);
d6.94 (m,1H); d7.07e7.10 (m,2H); d7.24e7.28 (m,1H); d7.34 (s,1H).
MS(TOF) 353.9 (Mþ).
4.2.2.11. 1-((2-Chlorothiazol-5-yl)methyl)-N-(2,6-dichlorobenzyl)-N-
methylpiperidin-4-amine (HSP70-31). 1H NMR (300 MHz, CDCl3-d):
d1.76e1.84 (m,2H); d2.08 (m,2H); d2.26 (m,2H); d2.56 (s,3H);
d3.01e3.04 (m,1H); d3.67 (m,2H); d3.86 (s,2H); d7.15e1.17 (s,1H);
d7.28e7.30 (t,1H); d7.32e7.36 (m,3H). MS(TOF) 404.8 (Mþ).
4.2.3. General procedure for the synthesis of compounds HSP70-
(32e34)
General procedure 3: General procedures 1: 2-Chloro-5-(chlor-
omethyl)thiazole (8.40 g, 50 mmol), tert-butyl piperidin-4-
ylcarbamate (50 mmol), and anhydrous K2CO3 (6.90 g, 50 mmol)
were to a 1000 ml three-necked ﬂask containing 300 ml of
dimethyl formamide (DMF). The mixture was stirred at room
temperature for 6 h. A large amount of ice water was added to
precipitate a solid. The solid was washed with large amounts of
petroleum ether, ﬁltered, and dried in a vacuum. A white powder
consisting of tert-butyl 1-((2-chlorothiazol-5-yl)methyl)piperidin-
4-ylcarbamate (3d, 16.90 g) was obtained (yield 98%).
One part F3CCOOH was added to 10 mmol of tert-butyl 1-((2-
chlorothiazol-5-yl)methyl)piperidin-4-ylcarbamate in anhydrous
dichloroethane (50 ml). The solution was stirred at room temper-
ature for 5 h. The solution was removed at 35 C under a vacuum
and recrystallized from ethanol-ethyl acetate to yield a white
powder. A stirred solution of white powder (5 mmol) in DMF
(30 ml) at room temperature was treated with substituted benzyl
chloride (5.1 mmol) and anhydrous K2CO3 (5.1 mmol) for 4 h. The
solution was extracted with dichloromethane, dried with anhy-
drous MgSO4, ﬁltered, and concentrated to provide yellow oily
residue that was puriﬁed by ﬂash chromatography to yield the
desired product as a white powder, HSP70-(32e34).
4.2.3.1. 1-((2-Chlorothiazol-5-yl)methyl)-N-(3,4-dichlorobenzyl)
piperidin-4-amine (HSP70-32). 1H NMR (300 MHz, CDCl3-d):
d1.44e1.45 (m,2H); d1.871 (m,2H); d2.09e2.10 (d,2H); d2.51
(m,1H); d2.86e2.89 (d,2H); d3.64e3.65 (d,2H); d3.78 (s,2H);
d7.17e7.19 (dd,1H); d7.34 (s,1H); d7.38e7.41 (d,1H); d7.46 (d, 1H).
MS(TOF) 390.8 (Mþ).
4.2.3.2. 1-((2-Chlorothiazol-5-yl)methyl)-N-(4-ﬂuorobenzyl)piper-
idin-4-amine (HSP70-33). 1H NMR (300 MHz, CDCl3-d): d1.46e1.51
(m,2H); d1.89e1.92 (m,2H); d2.05e2.12 (d,2H); d2.54e2.56 (m,1H);
d2.87e2.90 (d,2H); d3.64 (s,2H); d3.80 (s,2H); d6.99e7.04 (m,2H);
d7.31e7.34 (d,3H). MS(TOF) 339.9 (Mþ).
4.2.3.3. N-(3-chlorobenzyl)-1-((2-chlorothiazol-5-yl)methyl)piper-
idin-4-amine (HSP70-34). 1H NMR (300 MHz, CDCl3 CDCl3-d):
d1.43e1.46 (m,2H); d1.88e1.92 (m,2H); d2.07e2.13 (m,2H); d2.53
(m,1H); d2.86e2.90 (d,2H); d3.64 (s,2H); d3.81 (s,2H); d7.21e7.26
(m,3H); d7.34e7.35 (m,2H). MS(TOF) 356.3 (Mþ).
4.2.4. General procedure for the synthesis of compounds HSP70-
(35e56)
General procedure 4: 2, 4-dichloropyrimidine (40 mmol), tert-
butyl methyl(piperidin-4-yl)carbamate (41 mmol), and anhydrous
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containing 300 ml of DMF. The mixture was stirred at room tem-
perature for 6 h. A large amount of ice water was added to pre-
cipitate a solid. The solid was washed with large amounts of
petroleum ether, ﬁltered, and dried in a vacuum. Flash chroma-
tography (ethyl acetate-petroleum ether, 1:2) of the residue was
performed to obtain white powder 3b (tert-butyl 1-(2-
chloropyrimidin-4-yl) piperidin-4-yl (methyl)carbamate).
A solution of 3b (20 mmol) in anhydrous THF (100 ml) was
treated with CH3SNa or CH3ONa (30 mmol) and KI (20 mmol) and
reﬂuxed for 8 h. The mixture was cooled to room temperature in a
water bath. Solvent was removed under vacuum at 50 C. The
residue was dissolved in water, extracted with ethyl acetate, dried
over anhydrous Na2SO4, and ﬁltered. The organic phase was
removed under a vacuum at 45 C to obtain colorless oily residue
4d.
The colorless oily residue (10 mmol) was dissolved in
dichloromethane (50 ml). An excess of triﬂuoroacetic acid was
added in an ice bath. The mixture was stirred at room temperature
for 5 h. Solvent was removed under a vacuum to obtain yellow oily
residue 5d.
A solution of yellow oily residue 5d (0.3 mmol) was dissolved in
DMF (5 ml). Anhydrous K2CO3 (0.31 mmol) and substituted benzyl
chloride (0.31 mmol) were added, and the solution was stirred at
room temperature for 4 h. A total of 40ml water was added, and the
compound was extracted with dichloromethane and dried with
Na2SO4, and the solvent was removed to produce a colorless oily
substance, HSP70-(35e56).
4.2.4.1. N-(4-ﬂuorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-4-
yl)piperidin-4-amine (HSP70-35). 1H NMR (300 MHz, CDCl3-d):
d1.56e1.60 (m,2H); d1.90e1.93 (d,2H); d2.20 (s,3H); d2.53 (s,3H);
d2.73 (m,1H); d2.85e2.92 (m,2H); d3.57 (s,2H); d4.47e4.49 (d,2H);
d6.21e6.23 (d,1H); d6.99e7.03 (t,2H); d7.28e7.31 (m,2H);
d8.01e8.03 (d,1H). MS(TOF) 346.5 (Mþ).
4.2.4.2. 4-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)
amino)methyl) benzonitrile (HSP70-36). 1H NMR (300 MHz, CDCl3-
d): d1.55e1.59 (m,2H); d1.91e1.94 (d,2H); d2.21 (s,3H); d2.50
(s,3H); d2.75 (m,1H); d2.84e2.90 (t,2H); d3.65 (s,2H); d4.48 (d,2H);
d6.21e6.22 (d,1H); d7.46e7.48 (d,3H); d7.61e7.63 (d,2H);
d8.01e8.02 (d,1H). 13C NMR (DMSO, 100 MHz) d13.90; 27.80; 37.97;
43.40; 57.29; 60.83; 99.58; 109.95; 119.52; 129.63; 132.63; 146.97;
156.06; 160.77; 170.48. MS(TOF) 353.5 (Mþ).
4.2.4.3. N-(2-chloro-6-ﬂuorobenzyl)-N-methyl-1-(2-(methylthio)
pyrimidin-4-yl)piperidin-4-amine (HSP70-37). 1H NMR (300 MHz,
CDCl3-d): d1.62e1.69 (m,2H); d1.97e2.00 (d,2H); d2.28 (s,3H);
d2.50 (s,3H); d2.85e2.92 (t,3H); d3.71 (s,2H); d4.5 (s,2H);
d6.21e6.23 (d,1H); d6.99e7.05 (m,1H); d7.20e7.22 (m,2H);
d8.00e8.02 (d,1H). 13C NMR (DMSO, 100 MHz) d13.90; 27.56; 37.19;
43.52; 48.32; 61.48; 99.56; 114.72; 125.42; 126.08; 130.40; 135.96;
136.02; 156.06; 160.75; 163.29; 170.48.MS(TOF) 380.9 (Mþ).
4.2.4.4. N-(3,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyr-
imidin-4-yl)piperidin-4-amine (HSP70-38). 1H NMR (300 MHz,
CDCl3-d): d1.55e1.57 (m,2H); d1.90e1.93 (d,2H); d2.20 (s,3H); d2.50
(s,3H); d2.74e2.90 (m,3H); d3.55 (s,2H); d4.48 (s,2H); d6.20e6.22
(d,1H); d7.19 (s,1H); d7.37e7.45 (m,2H); d8.00e8.02 (d,1H).
MS(TOF) 397.4 (Mþ).
4.2.4.5. N-(3-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-
4-yl)piperidin-4-amine (HSP70-39). 1H NMR (300 MHz, CDCl3-d):
d1.57e1.60 (m,2H); d1.90e1.93 (d,2H); d2.22 (s,3H); d2.52 (s,3H);
d2.74 (m,1H); d2.89e2.90 (m,2H); d3.58 (s,2H); d4.47e4.49 (d,2H);d6.21e6.23 (d,1H); d7.24e7.28 (m,3H); d7.36 (s,1H); d8.02e8.03
(d,1H). MS(TOF) 362.9 (Mþ).
4.2.4.6. N-(2,4-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyr-
imidin-4-yl)piperidin-4-amine (HSP70-40). 1H NMR (300 MHz,
CDCl3-d): d1.64e1.68 (m,2H); d1.96 (d,2H); d2.27 (s,3H); d2.53
(s,3H); d2.86e2.89 (t,3H); d3.89 (s,2H); d4.54 (m,2H); d6.23e6.24
(d,1H); d7.17e7.19 (t,1H); d7.32e7.34 (d,2H); d8.02e8.04 (d,1H). 13C
NMR (DMSO, 100 MHz) d13.39; 27.30; 37.21; 38.87; 42.95; 53.97;
60.57; 99.07; 127.18; 128.59; 131.87; 133.91; 136.47; 155.55;
160.25; 169.97. MS(TOF) 397.4 (Mþ).
4.2.4.7. 2-((Methyl(1-(2-(methylthio)pyrimidin-4-yl)piperidin-4-yl)
amino)methyl) benzonitrile (HSP70-41). 1H NMR (300 MHz, CDCl3-
d): d1.59e1.65 (m,2H); d1.96e1.99 (d,2H); d2.21 (s,3H); d2.51
(s,3H); d2.82e2.93 (t,3H); d3.80 (s,2H); d4.50e4.52 (m,2H);
d6.22e6.23 (d,1H); d7.35e7.38 (m,1H); d7.56e7.57 (m,2H);
d7.64e7.66 (d,1H); d8.01e8.02 (d,1H). MS(TOF) 353.5 (Mþ).
4.2.4.8. N-(2,6-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyr-
imidin-4-yl)piperidin-4-amine (HSP70-43). 1H NMR (300 MHz,
CDCl3-d): d1.63e1.67 (m,2H); d1.94e1.97 (d,2H); d2.24 (s,3H);
d2.86e2.90 (m,3H); d3.87 (s,2H); d3.94 (s,3H); d4.51e4.53 (m,2H);
d6.21e6.22 (d,1H); d7.13e7.17 (t,1H); d7.30e7.33 (m,2H);
d8.02e8.03 (d,1H). 13C NMR (DMSO,100MHz) d13.39; 26.93; 36.09;
38.87; 43.14; 52.22; 60.95; 99.05; 128.64; 128.59; 129.72; 134.72;
136.09; 155.57; 160.23; 169.97. MS(TOF) 396.3(Mþ).
4.2.4.9. N-methyl-N-(4-methylbenzyl)-1-(2-(methylthio)pyrimidin-
4-yl)piperidin-4-amine (HSP70-42). 1H NMR (300 MHz, CDCl3-d):
d1.58e1.62 (m,2H); d1.92e1.95 (d,2H); d2.23 (s,3H); d2.36 (s,3H);
d2.52 (s,3H); d2.76 (m,1H); d2.85e2.92 (t,2H); d3.59 (s,2H); d4.47
(m,2H); d6.21e6.23 (d,1H); d7.14e7.16 (d,2H); d7.22e7.24 (d,2H);
d8.02e8.03 (d,1H). MS(TOF) 342.5 (Mþ).
4.2.4.10. N-(2,5-dichlorobenzyl)-N-methyl-1-(2-(methylthio)pyr-
imidin-4-yl)piperidin-4-amine (HSP70-44). 1H NMR (300 MHz,
CDCl3-d): d1.58e1.62 (m,2H); d1.92e1.95 (d,2H); d2.25 (s,3H);
d2.52 (s,3H); d2.86e2.87 (m,1H); d2.89e2.93 (t,2H); d3.67 (s,2H);
d4.49e4.51 (m,2H); d6.22e6.23 (d,1H); d7.23e7.26 (dd,1H);
d7.38e7.45 (s,1H); d7.45e7.47 (d,1H); d8.02e8.04 (d,1H). MS(TOF)
397.4 (Mþ).
4.2.4.11. N-(3-ﬂuorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-
4-yl)piperidin-4-amine (HSP70-45). 1H NMR (300 MHz, CDCl3-d):
d1.57e1.61 (m,2H); d1.92e1.95 (d,2H); d2.23 (s,3H); d2.52 (s,3H);
d2.86e2.87 (m,1H); d2.89e2.93 (t,2H); d3.61 (s,2H); d4.48e4.50
(m,2H); d6.22e6.23 (d,1H); d6.95 (t,1H); d7.09e7.11 (m,2H); d7.29
(s,1H); d8.02e8.04 (d,1H). MS(TOF) 346.5 (Mþ).
4.2.4.12. N-(2-chlorobenzyl)-N-methyl-1-(2-(methylthio)pyrimidin-
4-yl)piperidin-4-amine (HSP70-46). 1H NMR (300 MHz, CDCl3-d):
d1.57e1.67 (m,2H); d1.94e1.97 (d,2H); d2.27 (s,3H); d2.76e2.79
(m,1H); d2.88e2.94 (t,2H); d3.72 (s,2H); d3.95 (s,3H); d4.48e4.50
(m,2H); d6.21e6.22 (d,1H); d7.18e7.26 (m,2H); d7.35e7.37 (dd,1H);
d7.49e7.51 (d,1H); d8.02e8.04 (d,1H). 13C NMR (DMSO, 100 MHz)
d13.90; 27.80; 37.70; 43.48; 55.02; 61.10; 99.58; 127.50; 128.93;
129.71; 131.20; 133.63; 137.66; 156.08; 160.77; 170.48. MS(TOF)
361.9 (Mþ).
4.2.4.13. N-(2-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-meth-
ylpiperidin-4-amine (HSP70-47). 1H NMR (300 MHz, CDCl3-d):
d1.60e1.64 (m,2H); d1.95e1.98 (d,2H); d2.27 (s,3H); d2.52 (s,3H);
d2.87e2.88 (m,1H); d2.91e2.94 (t,2H); d3.72 (s,2H); d4.49e4.50
(m,2H); d6.21e6.24 (d,1H); d7.20e7.26 (m,2H); d7.35e7.37 (d,1H);
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4.2.4.14. 4-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-48). 1H NMR (300 MHz, CDCl3-
d): d1.54e1.58 (m,2H); d1.89e1.92 (d,2H); d2.20 (s,3H); d2.72
(m,1H); d2.85e2.92 (t,2H); d3.64 (s,2H); d3.92 (s,3H); d4.45e4.48
(m,2H); d6.19e6.20 (d,1H); d7.44e7.46 (d,2H); d7.59e7.61 (d,2H);
d7.49e7.51 (d,1H); d8.01e8.02 (d,1H). MS(TOF)337.4 (Mþ).
4.2.4.15. 2-(((1-(2-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-49). 1H NMR (300 MHz, CDCl3-
d): d1.60e1.64 (m,2H); d1.97e2.00 (d,2H); d2.23 (s,3H); d2.84e2.94
(m,3H); d3.82 (s,2H); d3.95 (s,3H); d4.49e4.52 (m,2H); d6.21e6.22
(d,1H); d7.31e7.39 (m,1H); d7.57e7.58 (m,2H); d7.65e7.67 (d,1H);
d8.03e8.04 (d,1H). MS(TOF) 337.4 (Mþ).
4 .2 .4 .16 . 1-(2-Methoxypyr imid in-4-yl ) -N-methyl -N-(4-
methylbenzyl)piperidin-4-amine (HSP70-50). 1H NMR (300 MHz,
CDCl3-d): d1.57e1.61 (m,2H); d1.91e1.92 (d,2H); d2.22 (s,3H); d2.35
(s,3H); d2.74 (m,1H); d2.86e2.92 (t,2H); d3.58 (s,2H); d3.94 (s,3H);
d4.45e4.47 (m,2H); d6.20e6.21 (d,1H); d7.13e7.15 (dd,2H);
d7.21e7.23 (dd,2H); d8.02e8.03 (d,1H). MS(TOF) 326.4 (Mþ).
4.2.4.17. N-(2,5-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-
methylpiperidin-4-amine (HSP70-51). 1H NMR (300 MHz, CDCl3-d):
d1.57e1.61 (m,2H); d1.92e1.95 (d,2H); d2.24 (s,3H); d2.76 (m,1H);
d2.86e2.93 (t,2H); d3.67 (s,2H); d3.93 (s,3H); d4.47e4.50 (m,2H);
d6.20e6.21 (d,1H); d7.22e7.25 (dd,2H); d7.37 (d,1H); d7.45e7.47
(d,1H); d8.02e8.03 (d,1H). MS(TOF) 381.3 (Mþ).
4.2.4.18. N-(3,4-dichlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-
methylpiperidin-4-amine (HSP70-52). 1H NMR (300 MHz, CDCl3-d):
d1.54e1.60 (m,2H); d1.92e1.95 (d,2H); d2.24 (s,3H); d2.76 (m,1H);
d2.90e2.92 (t,2H); d3.55 (s,2H); d3.93 (s,3H); d4.48 (s,2H);
d6.19e6.21 (d,1H); d7.17e7.19 (d,2H); d7.30e7.44 (m,1H);
d8.01e8.03 (d,1H). MS(TOF) 381.3 (Mþ).
4.2.4.19. N-(2-chloro-6-ﬂuorobenzyl)-1-(2-methoxypyrimidin-4-yl)-
N-methylpiperidin-4-amine (HSP70-53). 1H NMR (300 MHz, CDCl3-
d): d1.63e1.66 (m,2H); d1.95e1.98 (d,2H); d2.26 (s,3H); d2.78
(m,1H); d2.86e2.92 (t,2H); d3.74 (s,2H); d3.93 (s,3H); d4. 51 (s,2H);
d6.20e6.22 (d,1H); d6.99e7.01 (m,2H); d7.19e7.21 (m,1H);
d8.01e8.03 (d,1H). MS(TOF) 364.8 (Mþ).
4.2.4.20. N-(3-chlorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-meth-
ylpiperidin-4-amine (HSP70-54). 1H NMR (300 MHz, CDCl3-d):
d1.55e1.62 (m,2H); d1.91e1.94 (d,2H); d2.21 (s,3H); d2.74 (s,1H);
d2.85e2.90 (t,2H); d3.58 (s,2H); d3.93 (s,3H); d4.48 (m,2H);
d6.19e6.21 (d,1H); d7.23 (m,2H); d7.34 (s,2H); d8.00e8.02 (d,1H).
MS(TOF) 346.9 (Mþ).
4.2.4.21. N-(3-ﬂuorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-meth-
ylpiperidin-4-amine (HSP70-55). 1H NMR (300 MHz, CDCl3-d):
d1.56e1.64 (m,2H); d1.91e1.94 (d,2H); d2.22 (s,3H); d2.74e2.75
(m,1H); d2.86e2.93 (t,2H); d3.60 (s,2H); d3.94 (s,3H); d4.46e4.49
(m,2H); d6.20e6.21 (d,1H); d6.93e6.97 (t,2H); d7.08e7.11 (m,2H);
d7.25e7.30 (m,1H); d8.02e8.04 (d,1H). MS(TOF) 330.4 (Mþ).
4.2.4.22. N-(4-ﬂuorobenzyl)-1-(2-methoxypyrimidin-4-yl)-N-meth-
ylpiperidin-4-amine (HSP70-56). 1H NMR (300 MHz, CDCl3-d):
d1.56e1.60 (m,2H); d1.91e1.94 (d,2H); d2.20 (s,3H); d2.74 (s,1H);
d2.84e2.90 (t,2H); d3.58 (s,2H); d3.93 (s,3H); d4.47 (s,2H);
d6.18e6.20 (d,1H) d6.98e7.02 (t,2H); d7.30 (m,2H); d7.25e7.30
(m,1H); d8.00e8.02 (d,1H). MS(TOF) 330.4 (Mþ).4.2.5. General procedure for the synthesis of compounds HSP70-
(57e67)
General procedure 5: 4, 6-dichloropyrimidine was processed
instead of 2, 4-dichloropyrimidine as described in General proce-
dure 4 to provide the product HSP70-(57e67).
4.2.5.1. N-(2-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methyl-
piperidin-4-amine (HSP70-57). 1H NMR (300 MHz, CDCl3-d):
d1.60e1.67 (m,2H); d1.93e1.96 (d,2H); d2.27 (s,3H); d2.77 (m,1H);
d2.85e2.92 (t,2H); d3.72 (s,2H); d3.93 (s,3H); d4.40e4.44 (m,2H);
d5.86 (s,1H); d7.20e7.26 (m,2H); d7.35e7.37 (dd,1H); d7.49e7.51
(d,1H); d8.34 (s,1H). MS(TOF) 346.9 (Mþ).
4.2.5.2. 1-(6-Methoxypyrimidin-4-yl)-N-methyl-N-(4-methylbenzyl)
piperidin-4-amine (HSP70-58). 1H NMR (300 MHz, CDCl3-d):
d1.58e1.62 (m,2H); d1.91e1.94 (d,2H); d2.22 (s,3H); d2.35 (s,3H);
d2.74 (m,2H); d2.83e2.90 (t,2H); d3.58 (s,2H); d3.93 (s,3H);
d4.38e4.42 (m,2H); d5.85 (s,1H); d7.13e7.15 (d,2H); d7.22e7.24
(d,2H); d8.34 (s,1H). MS(TOF) 326.4 (Mþ).
4.2.5.3. N-(2,6-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-
methylpiperidin-4-amine (HSP70-59). 1H NMR (300 MHz, CDCl3-d):
d1.63e1.67 (m,2H); d1.93e1.96 (d,2H); d2.24 (s,3H); d2.83e2.90
(m,3H); d3.87 (s,2H); d3.93 (s,3H); d4.43e4.46 (m,2H); d5.86 (s,1H);
d7.15e7.17 (t,1H); d7.29e7.32 (m,2H); d8.34 (s,1H). MS(TOF) 381.3
(Mþ).
4.2.5.4. N-(3,4-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-
methylpiperidin-4-amine (HSP70-60). 1H NMR (300 MHz, CDCl3-d):
d1.43e1.58 (m,2H); d1.88e1.90 (m,2H); d2.19 (s,3H); d2.72 (m,1H);
d2.82e2.89 (m,2H); d3.53 (s,2H); d3.91 (s,3H); d4.38e4.42 (m,2H);
d5.84 (s,1H); d7.16 (s,1H); d7.37e7.44 (m,2H); d8.32 (s,1H). MS(TOF)
381.3 (Mþ).
4.2.5.5. N-(4-ﬂuorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methyl-
piperidin-4-amine (HSP70-61). 1H NMR (300 MHz, CDCl3-d):
d1.56e1.62 (m,2H); d1.89e1.92 (m,2H); d2.19 (s,3H); d2.72 (s,1H);
d2.82e2.89 (m,2H); d3.56 (s,2H); d3.88 (s,3H); d4.38e4.41 (m,2H);
d5.84 (s,1H); d6.98e7.02 (t,1H); d7.27e7.29 (m,2H); d8.32 (s,1H).
MS(TOF) 330.4 (Mþ).
4.2.5.6. N-(3-chlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-methyl-
piperidin-4-amine (HSP70-62). 1H NMR (300 MHz, CDCl3):
d1.55e1.62 (m,2H); d1.89e1.92 (m,2H); d2.20 (s,3H); d2.72 (m,1H);
d2.83e2.89 (m,2H); d3.57 (m,2H); d3.91 (s,3H); d4.38e4.41 (m,2H);
d5.83 (s,1H); d7.23 (m,3H); d7.34 (s,1H); d8.32 (s,1H). MS(TOF) 346.9
(Mþ).
4.2.5.7. N-(2-chloro-6-ﬂuorobenzyl)-1-(6-methoxypyrimidin-4-yl)-
N-methylpiperidin-4-amine (HSP70-63). 1H NMR (300 MHz, CDCl3-
d): d1.59e1.68 (m,2H); d1.94e1.96 (m,2H); d2.25 (s,3H); d2.75
(m,1H); d2.84e2.87 (m,2H); d3.73 (s,2H); d3.91 (s,3H); d4.42e4.45
(m,2H); d5.84 (s,1H); d6.99 (t,1H); d7.19 (d,2H); d8.32 (s,1H).
MS(TOF) 364.8 (Mþ).
4.2.5.8. 2-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-64). 1H NMR (300 MHz, CDCl3):
d1.58e1.62 (m,2H); d1.93e1.96 (m,2H); d2.20 (s,3H); d2.72 (m,1H);
d2.83e2.87 (m,2H); d3.78 (s,2H); d3.91 (s,3H); d4.41e4.44 (m,2H);
d5.84 (s,1H); d7.35 (s,3H); d7.54 (s,1H); d7.63e7.65 (d,1H); d8.32
(s,1H). MS(TOF) 337.4 (Mþ).
4.2.5.9. 4-(((1-(6-Methoxypyrimidin-4-yl)piperidin-4-yl)(methyl)
amino)methyl) benzonitrile (HSP70-65). 1H NMR (300 MHz, CDCl3):
d1.55e1.61 (m,2H); d1.88e1.91 (m,2H); d2.22 (s,3H); d2.71 (m,1H);
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d5.8 (s,1H); d7.26 (s,3H); d7.44e7.46 (d,1H); d7.60e7.62 (d,1H);
d8.32 (s,1H). MS(TOF) 337.4 (Mþ).
4.2.5.10. N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-
methylpiperidin-4-amine (HSP70-66). 1H NMR (300 MHz, CDCl3):
d1.59e1.62 (m,2H); d1.91e1.94 (m,2H); d2.25 (s,3H); d2.75 (m,1H);
d2.85e2.92 (m,2H); d3.66 (s,2H); d3.93 (s,3H); d4.41e4.44 (m,2H);
d5.86 (s,1H); d7.23e7.25 (t,1H); d7.38 (m,1H); d7.45e7.47 (m,1H);
d8.34 (s,1H). MS(TOF) 381.3 (Mþ).
4.2.5.11. N-(2,5-dichlorobenzyl)-1-(6-methoxypyrimidin-4-yl)-N-
methylpiperidin-4-amine (HSP70-67). 1H NMR (300 MHz, CDCl3-d):
d1.58e1.64 (m,2H); d1.91e1.94 (m,2H); d2.21 (s,3H); d2.74 (m,1H);
d2.84e2.91 (m,2H); d3.61 (m,2H); d3.93 (s,3H); d4.40e4.43 (m,2H);
d5.86 (s,1H); d6.95 (t,1H); d7.11 (m,2H); d7.28e7.30 (s,2H); d8.34
(s,1H). MS(TOF) 330.4 (Mþ).
4.3. Biological evaluation
4.3.1. Cell viability assay
A luminescent signal indicating the ATP levels was used as a
marker of cell viability. The breast cancer cell lines BT474, BT/
LapR1.0, MDA-MB-361, SK-BR3, SK/LapR1.0 and MDA-MB-453 were
selected for the cell viability assays. The cell lines were obtained
from the American Type Culture Collection (ATCC). The epidermal
growth factor (EGFR: ErbB-1, ErbB-2) tyrosine kinase inhibitor
lapatinib (10 mM in DMSO, BioVision, Cat: 1624-100, Lot: 50324)
was used as the positive control. The amount of ATP was estimated
with the use of an ATPlite kit (CellTiter-Glo Substrate, Promega,
Part: G755B, Lot: 32513501, EXP: 2014-05) according to the man-
ufacturer's protocol. Brieﬂy, the cells were trypsinized in 1 mL of
0.25% trypsin (Gibco) supplemented with 2 mL of medium (con-
taining 10% FBS, Gibco) and seeded (1  105 cells/mL, 50 mL/well,
5000 cells/well) into 96-well plates. The plates were incubated for
24 h at 37 C. The compounds were diluted to 10, 5, 2.5, 1.25, 0.625,
0.31, 0.16, 0.08, 0.04 and 0 mM. The serially diluted compounds or
control (50 mL) were added to each well in triplicate. The cells were
incubated for 72 h at 37 C. A volume of the CellTiter-Glo Reagent
(50 mL) equal to the volume of the cell culture medium present in
each well was added. The plates were shaken for 3 min on an
orbital shaker to induce cell lysis. To stabilize the luminescent
signal, the platewas incubated at room temperature for 10min. The
liquid supernatant (100 mL/well) was aspirated, and the lumines-
cent signal was measured. The cell viability was determined based
on the luminescence:
cell viability ð%Þ ¼ RLUexperimental group=RLUblank group  100%
[28].
4.3.2. Surface plasmon resonance (SPR) analyses
SPR studies of HSP70 inhibitors were performed using optical
biosensor Biacore T100 (GE Company) as reported elsewhere
[16,17]. Brieﬂy, human HSP70 (ADI-ESP-550-D, Enzo Life Sciences)
was immobilized on a CM5 sensor chip (GE) using 10 mmol/L
phosphate-buffered saline (PBS), pH 5.0, RU ¼ 11209. Binding ex-
periments were performed at 25 C using a ﬂow rate of 30 mlml1,
with 90 s of monitoring for association and 120 s of monitoring for
dissociation. The complete binding study was performed using an
eight-point concentration series (0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, and
10 mM), which were prepared with 5% DMSO in PBS. Different
concentrations of compounds were typically injected over the
sensor chip, and 5% DMSO in PBS was used as a running buffer and
blank control. Ver-155008 was used as a positive control. The data
were processed using an equilibrium dissociation constant (Kd
value), which was calculated with the steady state model:Response ¼ Conc*Rmax=½concþ Kd þ offset.
4.3.3. Colorimetric determination of ATPase activity
The assay procedure was adopted from previous reports [19]
with some modiﬁcations where indicated. Stock solutions of mal-
achite green (0.1% w/v), polyvinyl alcohol (2.3% w/v), and ammo-
nium molybdate tetrahydrate (1% w/v in 1 M HCl) were prepared
and mixed with water at a ratio of 2:1:1:2 to prepare the malachite
green reagent, which is stable at room temperature for at least 2 h.
The reagent should be ﬁltered through a 0.22-mM membrane prior
to use when its color changes from dark brown to yellow. ATP,
malachite green, polyvinyl alcohol and ammonium molybdate
tetrahydrate were purchased from Sigma and used without further
puriﬁcation.
For compound screening, an aliquot of a master mixture of
DnaK:DnaJ (2.0 mM:3.5 mM) prepared in assay buffer (0.017% Triton
X-100, 100 mM TriseHCl, 20 mM KCl, and 6 mMMgCl2, pH 7.4) was
added to each well of a 96-well plate (14 mL per well). To this so-
lution, 1 mL of either one of the test compounds (5 mM) or DMSO
was added, and the plate was shaken for 10 min and incubated for
30 min at 37 C. Ten microliters of 2.5 mM ATP was added to start
the reaction. The ﬁnal reaction volume was 25 mL, and the con-
centration of the tested compounds was 200 mM. After 3 h of in-
cubation at 37 C, 80 mL of the malachite green reagent was added
to each well, and the plates were gently shaken. Immediately
following this step, 10 mL of 34% sodium citrate was added to
terminate the nonenzymatic hydrolysis of ATP. After the samples
were thoroughly mixed and incubated at 37 C for 15 min, the
OD620 was measured using a SpectraMax M5 (Molecular Devices,
Sunnyvale, CA, USA).
4.3.4. Acute toxicity test by single oral gavage with HSP70-36 in
mice
Seventy mice (KM) were randomly divided into seven groups,
with 10 mice per group (5 males and 5 females). HSP70-36 was
diluted to concentrations of 155.5, 129.6, 108.0, 90.0, 75.0, 62.5, and
52.0 mg*ml1 with 0.5% sodium carboxymethyl cellulose. The
ﬁxed-dose procedure was used for this test. According to the acute
toxicity test results, the mice received 1555, 1296, 1080, 900, 750,
625 and 520 mg*kg1 HSP70-36 via oral gavage and were contin-
uously observed for 14 days. Death and toxicity were recorded after
5 min, 10 min, 20 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 18 h, 1 d,
2 d, 3 d, 7 d and 14 d. The LD50 was calculated based on a statistical
analysis with SAS.
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